JARED SIMMONS Jared.simmons77@gmail.com

LinkedIn Profile

SUMMARY

• Conceptual and data-savvy writer with 9 years experience crafting mixed-media copy for HCP, DTC, and wellness clients • Fashioned 360º campaigns utilizing Web, TV, iPads, smartphones, social media, rich-media content, kiosks, and print • Managed creative staffers and freelance writers, building strong brands and capable teams through mentoring • Developed expertise in immunology, neurology, psychopharmacology, cardiology, digital home diagnostics, women's

health, electrosurgery, and urology

ADVERTISING EXPERIENCE

FREELANCE: New York, NY 1/2010—Present

CDM NY • Spearheaded multiple components of 360º brand launch across DTC and HCP projects, from kickoff through launch • Played instrumental role in crafting and refining concurrent projects based on client, MMLR, and FDA guidance, earning

FDA approval May 2016, for a novel antipsychotic treatment in Parkinson's disease

Lyonheart • Helped develop agency positioning and creative direction for new business oncology pitch, including 360º campaign

development and tactical exploration

Likeable Media • Created social media campaigns and pitched content for pharma, tech, lifestyle, and entertainment clients • Tailored copy to resonate with a range of demographics and across myriad social platforms to fuel brand growth

The CementBloc • Wrote HCP-targeted T1DM copy for simplewins™ PRO site update, and 360º digital campaign content for Bayer’s

Contour® USB launch—introducing the first glucometer with built-in diabetes management software • Mentored broad range of copywriters from junior-level freelancers to senior staff writers

McCann RCW • Created a 360° campaign including storyboards, scripts, Web content, and HCP podcasts for HIV brand, Prezista® • Produced Webcast about novel clinical study including demographic groups with limited access to HIV/AIDS research

STAFF WRITER:

Saatchi & Saatchi Wellness—Copy Supervisor New York, NY 6/2014—2/2015 • Generated consumer-facing 360º campaign materials for several Humira® indications and support programs • Collaborated with multiple departments on new-business pitches, rebranding initiatives, and concept development • Presented new creative to internal management, MLR review teams, and clients

Lyonheart (LLNS)—Senior Copywriter New York, NY 12/2008—9/2009 • Contributed daily copy for leading surgical devices, and worked directly with SVP and EVP on J&J business win • Developed message platforms and ads for key brands, product pipelines, and new business pitches • Crafted content and refined copy for Geodon® tablet PC, and created flash-animated pages for the Web

Harrison & Star—Senior Copywriter New York, NY 12/2007—12/2008 • Managed freelance writers, coordinated coverage, and critiqued HCP- and DTC-facing work for four Humira® indications • Maintained dynamic US and AI client relationships through frequent communication and presentations • Researched and honed messaging for new RA treatment paradigm, and crafted concepts for pitches and H&S brands

Cline, Davis, & Mann—Copywriter New York, NY 12/2005—12/2007 • Shaped Websites from wires to launch; built campaign concepts and developed various tactics • Nurtured strong client partnership through daily communication, and frequent copy and conceptual presentations • Helped launch a multicultural group, working to increase resonance with African Americans and Hispanics

EDUCATION

Skidmore College BA, English Literature Saratoga Springs, NY 1996—2000 High Honors & Departmental Honors 1998—2000

SKILLS

Digital MS Office, CS5, Adobe, Outlook, E-routing, Basecamp, AMA/AP editing, Mac/PC proficiency

JARED SIMMONS

Jared.simmons77@gmail.com LinkedIn Profile

Hyperlinks

Immunology

Diabetes (T1DM & T2DM)

• Bayer Diabetes HCP

• Bayer Diabetes DTC

• Welchol® HCP

TNF-α diseases

• Humira® HCP

• Humira® DTC

HIV/AIDS

• Prezista® HCP

• Prezista® DTC Neurology

Parkinson's disease psychosis

• Nuplazid® HCP Multiple sclerosis

• Extavia® HCP Women’s healthcare

• CombiPatch® HCP Gastrointestinal

• ConvaTec (ostomy) Consumer (dermatology)

• Avène

• Gyltone

CONTOUR USB CONTOUR BREEZE 2 SUMMARY

NO CODING ERRORS. NO MALTOSE INTERFERENCE. NO PROBLEM ~:"".:';:,'''"'UO

·Blyer mot ... IIrte no In!ellefence from ma ltOll and p lottDso .

EB Ireeze

Test strips MICROlIT 2 GWCOFACTS CONTOUR1"S

With No Coding"" technology and no maltose and galactose interterence," the uniQue B 3\'l!r portfolio delivers accurate information for more informed treatment decisions. >

A1CNow SELFCHECK Access Resource!

Simply vast

!Ill9 a simplyvast diabetes resource

ClIstomizab ~- 'l\lC'l~vels Free

sftflplewins '~P.-BQ,. es 1>1 rt , r11

si mplydelivered

Register tor simplewins~PRO Bayer's new Web resource fOf HCPs. pH ' 1'1 ' J

Simplified dialogue

A simplified diabetes dialogue

. . "'"''

is a sim plewin for you r patients

C!..Welcho{ "'.....,Hol

T_ gak, _ therapy

Home

AbDul Wel chol • Tho Wile"", J If." P",II. • _ 'II'oIehol '11011<,

• Tho Wile "'" DU .... o<.

LDL- C and At e Redu ctions With Welchol • .", ....... '- Sill ... ..... In

Primary H1 ... ~.1I1o

• Wolchol '- AtarYUlI.tln In PrIrnuy ",,.lIpIde .. 1I

• __ 'l'7 In p~"..,.,

",porlpld .....

• An AlII, .. II<. to Sl, tln Tlra>J. n In Primary "" .. pili ....

• Tho GLOWS PIo, ""'" In Typ. 2 0101101, .

• Tho Boy. Ploobi 5t"", h Typ. 2 0101101,.

• InU,tiog C<lmbinal ... "'''PI' In Typo 2 DIabne.

Flexible Dosing Opti ons • Or,1 S.,po .. jon .... D"IO,.

• 1010, f'«no.lalioo . . ... ~".

Support & Resou rces • P.,loot P~II •• • P",Ikj,n RooOlrC ••

ImpOOR $a!lJ\y Iolormation Prescribing Intormahon (l'Df) Welcllol Pall&rt Home

Welchol Newsletter : Si(plllp lor lJpdal!!S I!!I

AS AN ADJUNCT TO DIET AND EJa,RC/SE,

.. KNOCKS DOWN TWO, WITH ... I<""'''.hO .......... _ ~DA 'j , ......... ,_ ........ ....... ..,,,e ..... A,e,., _ w"h.,. ............. . __ 0<7 "'~rl¥l'''ml •.

Take Down LDL-C

We/chal signif icantly /ower'S LDL-C in type 2 diabetes and primary hyperlipidemia.

Safety Profile Support & Resources

Take Down A 1C We/chal is proven

effective in lowering A 1 C in type 2 diabetes

and primary hyperlipidemia.

WeICl'tOl ne"""'lel'licaq ,n oom t)'P<l 2 alaoetesand pnma...,. ~~P"11,pode""a ""mout oem,. syst<l""C8II~ at>s<>roed .

A pny,"oan-only m.o,,,oe oent<l, to reque . t "'mp1es, ",e",

'n1<>nna~"" "",I • .."..;," pm ... nta~oo., aM <><de, ma!<lna',

for ~OU' "fadoe.

,

Welchol for Oral Suspension QIle, yOUf patients ""t!1 ty!>e 2 nial>etes, and pnmBry ~ypen,po""""a, t!1e

cooV<lf"lienCfl of Oi'ICfI-aa"y <1<>,""11 ""m WeI<'ll<>l1<>t O<a, SU"!'M'"oo .

• LENIN UOIII:

(UNe/chor ~mHClI

T_ goals. _ therapy

Home

AbDul Welchol • Tho Wllehol JIf." P~II.

• _ 'IIo1e"" WlI"', • Tho '11l1ehol DlIIor,,,,,

LDL- C and At e Redu ctions With Welchol • .... _ '- 51n ... ..... In

Primary Hypo ....... "'

• III_II '- A'orYUutin In P"","" Hypo""o .. 11

• _ .... ,." In p~...,., IIyporlpld ....

• An l U" .. tI .. '" Sl. U. Tlra>Jon In PJImaty "" .. pili .....

• Tho GlOWS PIo, ""'" In Tn. 2 0 ....... .

• Tho Boy. Ploobl SI"'" In Typ. 2 a ........

• Inu.no; C<ImbIrIa, k>n ",.aPT In Typo 2 DIabote.

Flexible Dosing Opti ons • Or" 6.'po .. l00 .... DOIIIII' • Id1o, f<>mulatioo .. ... ~q.

Support & Resou rces • P.,lIot P",II ••

• P",skI •• RnOlr<O'

Impon:lfll SallJ\y lmormat,OIl Prescribing Intormahon (PDF) W8Ichol Patient Home

Welchol HewsllMll!f : Si(Jll Up lor Updates I!!I

LDL-C and A1C Reductions With Welchol Welchol provides power1ul benefits for patients with primary hypelipidemia, type 2 diabetes, or both

'M!1<1l<>l ;0 1118 ~rS! and 0111, 1118180, 8Pl"0veO as an Mlu~ct 10 o,et aM e~..,.", ... , 10 .. g nlflcaMy ,educe 00111 LDl-C and A Ie klr aOult

I"'~""IS \/t,1n PO""''''' Mype<lll"de mo8 and!<>< type 2 0'80018" Ma~ft VI\<llct!Ol 1"'''' flfSl""",,""" IKld-on l!1e,ap~ I<> Mlp l!1em ",:I"e ..... l!1e" goals.

The American ~at>e,.,s Assooa~"" and 1118 Amencan C.,.,eg8 of Ca,a,.,.og, emp/"III"'2e l!1at a IS cn~GIIIIO ,lid""" 001!1 A lC ana LDL-C ,n pa~ents w,1!1 Ij'pe 2 d,,,OOtes."

• Nean, 40% 01 adults w,1!1 Ij'pe 2 d,abete s "1""",, ..... 81evate<l LDL-C'

Wddiol etfoctiv<t( kIIocIos down WI..·C as "., add ·OO IhInClY 0' mooolli~~

• VI\<lI~ & S<mvastaM ,n Pnl'lllcY HypMlpjdem a

• IIIOII~ & AlO<Va'ta~n !n PnmacY Hyp<t11,p<de<rua

• IIIOI,dlol ~onol!1e,ag! ,n Pnma!), H!pe<t'p'dema

Ale Red uctions ExplOfe WoIct!OI a,nlcal ttlal data stt".,,"Il ,1Iduc>oos ,n A IC.

• t.ENOI MOllO

Wek:!lot has tlOO!1 shown 10 knock down A IC in ctinlcall~

• VW!4cnoi GLQ\I\§ Pllot Stud y on Type 2 D'8DeIe S

• IIIOIIcnoi a nd 1!le B8~s Pivotal Stud\' !n Type 2 o,,,OOtes

• WeI~ comoo""~",, Thft<ap! ,n h f?! 2 [)jaMIeS

Oral Suspension

WeI~ ofle,. coo"",."enl do",ng ,,!,~oo • .

, I.£NCN ~PE •

 

With NovoLoge, mealtime can be on your time.

Ask your do<tor if fast-acting Novolog" might be right for you_

II you're <urre"'ly .aklng 3 m@alllmeln,ulin,you ml9h. w~n"o .,k

)'<Iur doctor 3bou. fo,,-.cllng NOVOlO<jc. No''''-''!f work, 13, .. '" you

(an tak~ II ,00 lh~n e31 WIthin 5 to 10 mmUle1, r~l~r Ih.n 1~ 30 mmu'", y<lu h."" 10 w.It with "'gular human In,ulin

F ....... " ..,d N",",,-o¢ ... ' ... ft, ..... ~odomo<" oj "ovo No,,"'" '"' 01011 """" ""d~k ~W "9"" ,_ 1001"'-1<1 , .... "" ><I"

 

How is NovoLog® different?

I lo,oLog" helps ,OU f,,"p YO ut Idood suor on t3r~et. SoOJus"

Ile"oLoy· imintes lh" h,)d'" o'"n in sulin ,el"o>" onel ;,3ting ,ou CJ n hJ,,, " n"e i,,, t, I':'u,j sU'J" ,,)ntl,, 1 Jne' m.JI, .,tli cil 01 3/ h.lp ~ou g"t ,Ioset 10) ~OUI torg,t b l oo~ sU'lor 1;"" ls

Ilo,o L" t' ",,,f. s just li f e '"QuIJt IlUn,," in sulil1 But itl13S t'';,11 sli 'lM , modifi"d to NO', 105t'" in i'Jut 1'01;. SO ,'JU c.n tJf e rt ~nd "Jt " i1l1in 5 10 I 0 minute ,

' nd ~ou OJ n Uu stll o,e,Log" t" f ""p up ~ ith ,O UI " h"dul": 'OU ,nd ,e,u l d':'GIoO' mJ, ,djusl ",ut dc,so,];; 1" m' t(h "" ut "Jtin ~ . nd . ,;1i,il, ~.tte""

In d i c~ti o n s Jnd USJge: 11,:"e,L')'J"' ,.illsulin "p,,*DI'I' ''';~inl inj .cti,:, nl is J m,n-ma,J" in sulin th Jl i, us"d to ,ontrol high blood ,ugJr in ~d ult' Jnd th ild,"n " l1h ,jio',.t., mellitus

ImportJnt SJfety Inform Jtion:

, ... P ... • ..... ~"'""'-..... ... '"ObI"",, """""""'" 01 N""" N",do" "" 010" No«> N","'" ~" ,Igh" , ........ ,.0'..,.,., """"" ,."

1'1 more about FlexPen'"

d Important y Information

Novol['og" FI~~n· -----

 

Focus more on glucose control with less weight gain than other insulins:

Ask your doctor about switching from your current long·acting insulin to Levemi,...

If you'r~ CUrrOf\\ly tO~I"g a bo,.1 in.uhn,)'<Iu may want to \O",,<k,

.wltch'ng to l..".,m l" In dIfferent thon other typ<"> of In<uhn ~ou may

haye hl:ard al>out

l .... "" .. ;.. kmg-utmg inwlln that <.>n he lp you g'" to your blood .ugar goa l.

'I, """ . ," " '" ,"oolh, ' '''",, ', , .. ,'"'',''' "' , 1 ,, ' !" , " ".b"",,

lh""" "' .. """ ot, ' ~ilh .. m" "~" , ... "" "hI , .,' Ih" "PH ,, ' " .. " , .

Th' ""' "~OIO""" "" "hI " " b,tA· .. , l, ."," ,, ' otl"" " m"""" . ' ,,,,,,, ,, """'h It h .. b,,, " m, ... '" 0"" '" ,,,",,', ool" ... ~. It" "' , ', .. ~~ "',, th, ,~" " . , ,,,,,hi "'010 II" """" " l, .,..," Ih ... " . Th' ,,",' ·"" ' Ot b,,,fI,, to ,ot,,,,, "'" lh,m', h •. , 001 b,,, ,,""~h, '

~

Lev. mir' FleKPen· ----' ...... n· ..,d ..... ." .. ~. ,."", ..... ~_,"",k< of N"", """' ... W; 010"""'" N",d"l<. u"."U ,_. , ""]SO...., Ion, .. , '0 "

Pfizer Oncology Pipeline Introduction

In addition to RTK inhibition, Pfizer Oncology is currently researching other types of compounds against RCC. Pfizer Oncology is dedicated to the development of a diverse array of agents that target many of the molecules and processes dysregulated in RCC as well as in many other cancer types.

PFIzeR ReSeaRCH In RCC

One approach to RCC treatment being investigated by Pfizer Oncology is receptor tyrosine kinase (RTK) inhibition. RTK inhibition results in simultaneous antitumor and antiangiogenic activity that may lead to tumor stabilization and regression in 2 ways5,6:

>> Inhibiting tumor cell proliferation>> Inhibiting angiogenesis

Renal Cell Carcinoma (RCC)

Ren

al C

ell C

arci

nom

a (R

CC)

COMPOund ReSeaRCH PlaTFORM PHaSe OF deVelOPMenT

ticilimumab(CP-675,206)

Fully human monoclonal antibody (mab)

active against CTla4

Phase 1/2 combination

Oral RTK inhibitor

Potent inhibition of the VeGFR and PdGFR pathways

axitinib (aG-013736)

Phase 2

InSulIn-lIKe GROWTH FaCTOR I ReCePTOR (IGF-IR): an IMPORTanT TaRGeT In PROSTaTe CanCeR>> epidemiologic studies have established a link

between high circulating serum IGF-I levels and the risk of developing prostate cancer8

>> IGF-I signals IGF-IR, a tyrosine kinase receptor that has many essential biologic functions9:

— Cell survival — Transformation — Cell proliferation — angiogenesis — Metastasis

Prostate Cancer

One important approach in prostate cancer treatment being studied is inhibition of IGF-IR phosphorylation and signal transduction.

PROSTaTe CanCeR InCIdenCe and MORTalITy>> Worldwide, in 2002, there were 679,000

new cases of prostate cancer and 221,000 deaths attributed to prostate cancer1

>> In the united States, prostate cancer is the most commonly diagnosed cancer in men, with 234,460 cases diagnosed in 20057

>> Most cases of prostate cancer occur in men aged 65 years or older1

>> The incidence rates in the uS doubled from 1986 to 1992 with the introduction of Prostate Serum antigen (PSa) testing, and have since declined1

IGF-IR

IGF-IR

Prostate Cancer (CRCC)

Prostate Cancer

In addition to IGF-IR inhibition, Pfizer Oncology is currently researching other types of compounds against prostate cancer. Pfizer Oncology is dedicated to the development of a diverse array of agents that target many of the molecules and processes dysregulated in prostate cancer as well as in many other cancer types.

ReSeaRCH PlaTFORM PHaSe OF deVelOPMenTCOMPOund

Phase 1/2 combinationCP-751,871 Fully human monoclonal antibody (mab)

active against IGF-IR

Pros

tate

Can

cer

VEGFR VEGFR

Colorectal Cancer (CRC)

One approach in CRC treatment being studied is direct targeting of tyrosine kinase receptors.

Colorectal Cancer (CRCC)

One approach to prostate cancer treatment being investigated by Pfizer Oncology is IGF-IR inhibition.

>> a monoclonal antibody that binds and blocks IGF-IR signaling has shown immediate inhibition of IGF-IR activation and delayed down-regulation of IGF-IR on the cell surface10

>> Blocking IGF-IR function has been shown to reverse the transformed tumor cell as well as induce apoptosis of tumor cells9

>> Inhibition of IGF-IR may also sensitize tumor cells to traditional anticancer agents in a combination regimen9

CRC InCIdenCe and MORTalITy>> In 2002, there were 1,023,152 new cases of CRC

and 528,978 deaths worldwide1

>> The age standardized rate (aSR)* of incidence for CRC worldwide is 20.1 in men and 14.6 in women1

*aSR is per 100,000 people.

>> The worldwide aSR of mortality for CRC is 10.2 in men and 7.6 in women1

>> CRC incidence is more common in men than women and significantly rises in those older than 45 or 50 years of age11

>> Rates of CRC incidence and mortality are highest in Western countries and Japan, possibly due to diet, obesity, and lack of exercise1

>> In the united States, the annual associated cost for approximately 250,000 colorectal cancer–related hospitalizations is 5 billion dollars11

VeGFR: an IMPORTanT TaRGeT In CRC>> Vascular endothelial growth factor (VeGF) ligands

and their corresponding receptor tyrosine kinases (RTKs), VeGFRs, are thought to play a major role in the progression of CRC through the effect of VeGF/VeGFR signaling on tumor-associated angiogenesis12

>> VeGF ligands signal through the RTKs to regulate growth of new blood vessels, survival of immature blood vessels, lymphangiogenesis, and immune cell function12

>> VeGF has direct effects on endothelial cell functions, including12:

— activation — Survival — Proliferation — Migration

In addition to RTK inhibition, Pfizer Oncology is currently researching other types of compounds against CRC. Pfizer Oncology is dedicated to the development of a diverse array of agents that target many of the molecules and processes dysregulated in CRC as well as in many other cancer types.

Colorectal Cancer (CRC)

VeGFR exPReSSIOn In CRC

In general, 50% to 70% of colon cancers express VeGF12

— The expression of VeGF in colorectal cancer, either at the mRna or protein level, is reported to be higher than that in normal colonic mucosa13

— In addition, VeGF levels are higher in metastatic cell lines and colorectal cancer tissues than in nonmetastatic cells or tissues13

Both the proportion and intensity of VeGF expression are positively associated with the progression of colon carcinogenesis12,13

— The inverse correlation between VeGF expression and intratumoral microvessel density in CRC prognosis provides evidence for the role of angiogenesis as a therapeutic target in patients with colorectal cancer12

>>

>>

>> One approach to CRC treatment being investigated by Pfizer Oncology is RTK inhibition. Through direct targeting of tyrosine kinase receptors such as VeGFR and others such as platelet-derived growth factor receptor (PdGFR), KIT, and FlT3, multi-targeted RTK inhibitors exhibit both antiangiogenic and antitumor activities. Both tumor cell proliferation and blood vessel support of tumor growth are reduced through the interaction of these receptors with tyrosine kinase inhibitors14

COMPOund ReSeaRCH PlaTFORM PHaSe OF deVelOPMenT

ticilimumab(CP-675,206)

Fully human monoclonal antibody (mab)

active against CTla4

Phase 2 monotherapy

axitinib (aG-013736)

Oral RTK inhibitor

Potent inhibition of the VeGFR and PdGFR pathways

Phase 1/2 combination

Colo

rect

al C

ance

r

Activation of innate and immune responses

TLR9

Lung Cancer

TlR9: a POTenTIally IMPORTanT TaRGeT In lunG CanCeR

The human immune system has 12 toll-like receptors (TlRs), which initiate a variety of host defense mechanisms when activated.15,16 One such TlR, TlR9, is expressed in 2 types of human immune cells: plasmacytoid dendritic cells (pdCs) and B cells.17 TlR9 is activated by unmethylated CpG dinucleotides, which are found in foreign pathogens as well as synthetic oligodeoxynucleotides (Odns) containing unmethylated CpG motifs. When activated, TlR9 triggers a cascade of innate and adaptive immune responses that exert a variety of potent antitumor effects.

Two important approaches in lung cancer treatment being studied are receptor tyrosine kinase (RTK) inhibition and toll-like receptor 9 (TlR9) agonists.

lunG CanCeR InCIdenCe and MORTalITy

>> In 2002, there were 1,352,132 new cases of lung cancer and 1,178,918 deaths worldwide1

>> The age standardized rate (aSR)* of incidence for lung cancer worldwide is 35.5 in men and 12.1 in women1 *aSR is per 100,000 people.

>> The worldwide aSR of mortality for lung cancer is 31.2 in men and 10.3 in women1

>> Worldwide, lung cancer is the foremost cause of cancer-related mortality1

>> The risks of lung cancer are highest in the united States and europe1

Overall 5-year survival rates are less than 15%1

>>

Lung Cancer

For advanced non–small cell lung cancer (NSCLC)

Understanding your treatment with ABRAXANE

ABRAXANE®, in combination with carboplatin, is indicated for the first-line treatment of non–small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.

WHY has my doctor given me this brochure?

6

WHAT is ABRAXANE?

7

ABRAXANE is a kind of chemotherapy used to treat advanced NSCLC.

Chemotherapy is a kind of drug that works by killing cells that are growing and dividing, including cancer cells. ABRAXANE belongs to a class of chemotherapy drugs called taxanes. Taxanes are derived from yew trees and have been used by doctors for many years.

A recent large study demonstrated that 30% more patients had their tumors shrink with ABRAXANE and carboplatin (another chemotherapy drug) compared to a different chemotherapy (paclitaxel injection) and carboplatin.

• 170 of 521 patients responded to ABRAXANE and carboplatin

• 132 of 531 patients responded to paclitaxel injection and carboplatin

Non–small cell lung

cancer (NSCLC) is the

most common type of

lung cancer.

WHY has my doctor given me this brochure? WHAT is ABRAXANE®?

Your doctor gave you this brochure because you have advanced non–small cell lung cancer, also called NSCLC.

NSCLC is one of the 2 main types of lung cancer. The other type is small cell lung cancer. NSCLC is more common than small cell lung cancer. The 2 types are treated very differently from each other.

Your doctor has chosen to treat your NSCLC with a medicine called ABRAXANE® in combination with another drug called carboplatin.

This booklet provides information about NSCLC and ABRAXANE. It is also important to speak to a member of your healthcare team about any questions or concerns you have.

More patients had

their tumors shrink

with ABRAXANE and

carboplatin compared

with another treatment.

30%MORE PATIENTS HAD THEIR TUMORS SHRINK WITH

ABRAXANE& CARBOPLATIN

GRACE is a unique studyThe GRACE Study is the largest study to date in North America of treatment-experienced (TE) adultwomenwith HIV/AIDS to examine gender and race* differences in response to PREZISTA/r incombination with other antiretroviral (ARV) medication.2-4

• GRACE demonstrated that it is possible to recruit andretain large numbers of women,blacks, and Hispanicsinto US-based HIV/AIDS treatment studies2,3

• Themakeup of the study population—67%TEwomen and 33%TEmen—represents the population affected by HIV2

*Race was a secondary endpoint.Race analysis is not presented in this piece.

TibotecTherapeutics and GRACEAs a leader in the treatment of HIV/AIDS,Tibotec Therapeutics iscommitted to understanding theneeds ofwomen and people of colorwith HIV/AIDS,and expanding the clinical knowledge essentialto their treatment.

About the GRACE StudyThe GRACE Study looked at whether PREZISTA/r in combinationwith other ARVs would have a different effect in women comparedtomen.2

TE women,and particularly women of color,were the focusof the GRACE Study because of the disproportionate effectthat HIV/AIDS has in this population throughout the country.2,5

TEwomen have been underrepresented in trials to dateMore women are being diagnosed with HIV each year.Yet,despite the increasing numbers6:

• There is little information on howwomen,andparticularly women of color, respond to ARV treatment7

Increasing numbersmean an increasing need for information

Women account formore than one quarterof all newHIV cases in the US each year8

Women of color aredisproportionatelyaffected by HIV/AIDS9,10

Black women are 20 timesmorelikely to becomeHIV positive thanwhite women9

Women

Men

1/4

3/4

2004 2007

Asian or PacificIslander

American Indianor Alaskan Native

14%

66%12.7%

WhiteBlack

Hispanic

4.5% <1%

65%19%

15%

<1% <1%Asian or Pacific

IslanderAmerican Indianor Alaskan Native

WhiteBlack

Hispanic

Women living in the USn=152,962,259 (2007)10

Women livingwithHIV/AIDS in theUSn=146,692 (2007)*9

White women

Black women

“TheGRACE Study is an incrediblecontribution to theHIV andAIDScommunity.”1

DawnAveritt Bridge,Founder& Chair,TheWell Project

“Women are the growing face of HIV.”1

Linda Scruggs,Director of Programs,AIDSAlliance for Children,Youth,and Families

From 2004 to 2007, the number of blacks diagnosedwithHIV/AIDS increased each year.9

FPO

Please see PREZISTA Indication on the front cover.

Please see PREZISTA Important Safety Informationon pages 12-13.

*34 states with confidential name-based HIV infection reporting.

32

Home Contact Print Page Send to a Friend

About PREZISTA (darunavir) tablets Important Safety Information Product Information Search

®

About the GRACE Study

What Is GRACE?

GRACE is the largest HIV/AIDS study to date in North America of women who havereceived HIV treatment in the past. The GRACE Study looked at whetherPREZISTA/Norvir (ritonavir)* in combination with other antiretroviral (ARV)medications would have a different effect in women compared to men. All patients whoparticipated in the study received PREZISTA at a dose of 600 mg twice a day plusNorvir (ritonavir) at a dose of 100 mg twice a day in combination with otherantiretroviral (ARV) medications chosen by the study physicians.

Women who have received HIV treatment in the past, particularly women of color,were the focus of the GRACE Study because of the disproportionate effect thatHIV/AIDS has in this population throughout the country. Click on any of the links onthe left to learn more.

The Vision of GRACE

Tibotec Therapeutics, the sponsor of the GRACE Study, partnered with practitionerswho had experience and expertise treating women who received care in communityhealthcare settings and worked closely with communities nationwide to engage womenin healthcare.

The researchers recognized that women with HIV/AIDS have distinctive needs withrespect to participating in clinical trials and may require:

Transportation and child care

Counseling and/or emotional support from clinicians and other women livingwith HIV/AIDS

Information about benefits and risks of participation in clinical research

Additional assistance to stay involved

Support for Women With HIV/AIDS

A full support team for women with HIV/AIDS, particularly women of color, can helpthem connect to and stay in care for optimal treatment management.

What is GRACE?

A Search for Answers

Reaching Out

The Picture of GRACE

What Does GRACE Mean for People With HIV/AIDS Who Have Taken HIV Meds in the Past?

What Does GRACE Mean for Women With HIV/AIDS?

GRACE Resources

Click here for a brief videoabout the GRACE study.

GRACE in YourArea

Click here to find out aboutGRACE-related events going

on in your area.

GRACE ResourcesWant to know more aboutthe GRACE Study? Click

here to register for updates.

®

®

Visual: Type appears over photo silhouette of awoman’s face

VO: Women are a growing face of HIV/AIDS. Eachyear they account for...

GRACE Video Storyboard Page 1

Visual: Fades from silhouette to pie chart to VO copy

VO: ...more than one quarter of all newly diagnosedHIV cases in the United States. That’s approximately15,000 more women each year facing the challengesof living with HIV/AIDS.

Visual: Bar chart build showing racial disparity

VO: And, 80% of these women with HIV/AIDS arewomen of color.

Visual: Fade from chart to patients; headline fadesbefore VO begins

VO: Yet, there is little information on how womenrespond to HIV/AIDS treatment compared to men...

Visual: Patient images

VO: ...because not many women, especially womenof color, have participated in HIV clinical studies ofpeople who have taken HIV meds in the past—untilthe GRACE Study.

Visual: Running text banner across screen withbutterfly

VO: GRACE stands for Gender, Race, And ClinicalExperience. It is the largest study completed to datein North America in adult women with HIV/AIDSwho have taken HIV meds in the past.

Visual: Transition into GRACE logo Visual: Dr Fernando Garcia, Specialistin HIV/AIDS Care

Dr Fernando Garcia speaks: “Our vision, which isjust increase the opportunities and research in acommunity of color or minority groups and women…

80% of these women withHIV/AIDS are women of color.

80% of these womeHIV/AIDS are wome

14%Hispanic

66%Black

18%White

14%Hispanic

66Bl

18%White

Women are a growingface of HIV/AIDS.

Specialist in HIV/AIDS Care

I PREZIST.< (daruna~r) la~ets

PATIII!:NTS" CARe-GIVERS HEAL THCARE PROFESSIONALS COMMUNITY EDUCATORS

-_fA· B .... nc. gj PRElJ$f ....

~i_,.nlS.IioIVWO,."",. -

Bob. SW""'Q ~UlST"'·

--0t\I(I WO ..... CIlonll co.d,,"~i'".on GJO<le '"

'''''

• • _ •• , ..... "' •• _~ •• • ~"'d ""'n"'.., · .. _ afPREZlIT ...

AAk your Healthcare Professional If the PREZISTA­Experience Is right for you.

• Qnc.{lilly PREZlST"e (daruna";.) tal<en in COITIblnation wi". ON. Htv

meoICll~on. can help lower \'011' Yi!1lI k>ad Ind l<eep JIOO' HIV unol. COO~ (MI' '"

long .m!, "' • d lnlCIII 5!IJdy' of a imos14 yea~ (192 weeks), 1 001 of 10 U ulll wno Mid never taken HIV medications bel",,, ma lnlil lned undete<:labl. 1 vira l loadl ,. iln PREZISTA' p lus ri tooavi, and Truvada"',

• S" ImDoOIn15a1ltly 1'l1om\a1lD!l be low.

PREZlSTA. 15 tI1e number one pre scribed me<l ication In !fl, diU of p.roteSH

Inh lbitt:m lor patients ... "", beg in a new combination Htv Ih<I rapy.1

o An.~5~Jun. 201 2-JIJn"201 3

· ... ""j,,, .. ; .... ",. .......... , .., "",...,.,. P~ZlSl"''''''''fI&'''IODI\OO "'" _ • • ", lro')<))" .. ~ .... ..,"" .. &O!>i'l'O'J ""'''-II- j"-!.<I).

, ....... "" ............ Dyn.o""". Jo ... 2'(1.2 ......... 2~n ........... ...; ,..., .. 10< ..... "" _10 • .,.; • ....." 0" ..... "'''0>. F ... · ' ..... ........., .... 0" """"' ........ _ .

1009 ........ ' ..... .,. ..... ............. 04 ...................... .

•

Take a moment to learn more at HUMIRA.com or call 1.800.4HUMIRAAsk a dermatologist if HUMIRA is right for you.

HUMIRA is the #1 Prescribed Biologic Medication by Dermatologists2†

Who is HUMIRA for?HUMIRA is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

Important Safety Information1

What is the most important information I should know about HUMIRA? • Serious infections. HUMIRA can lower

your ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA.

• Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.

Tell your doctor about all of your health conditions, including if you:• Think you have an infection or are being

treated for infection. You should not start HUMIRA if you have any kind of infection unless your doctor says it is okay.

• Have symptoms of an infection, such as: fever, sweats, chills, muscle aches, cough, shortness of breath, blood in phlegm, weight loss, warm, red or painful skin, sores on your body, diarrhea, stomach pain, burning when you urinate, urinating more often than normal, or feeling very tired.

• Get a lot of infections or infections that keep coming back.

• Have diabetes.

• Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB.

• Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis.

• Have or have had hepatitis B.

• Are scheduled for major surgery.

• Have or have had cancer.

• Have numbness or tingling or a nervous system disease, such as multiple sclerosis or Guillain-Barré syndrome.

• Have or had heart failure.

• Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines.

• Are allergic to rubber, latex, or any HUMIRA ingredients.

• Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed.

• Take any other medicines. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).

Call your doctor right away if you have an infection or any symptoms of an infection while on HUMIRA.HUMIRA can cause other serious side effects, including:• Hepatitis B infection in carriers of

the virus. • Allergic reactions.• Nervous system problems. • Blood problems. • Heart failure (new or worsening). • Immune reactions including a

lupus-like syndrome. • Liver problems. • Psoriasis (new or worsening).

Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea.

These are not all of the possible side effects with HUMIRA. For more information, talk to your health care provider.HUMIRA is given by injection under the skin.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1.800.FDA.1088.

If you cannot afford your medication, contact: www.pparx.org or call the toll-free phone number (1.888.4PPA.NOW) for assistance.

With the HUMIRA Protection Plan your co-pay could be as low as $5 a month.*

* Eligibility restrictions apply. See card for details.

Please see additional Patient Information on the following pages.©2013 AbbVie Inc. | North Chicago, IL 60064 | 64Y-1196403 | May 2013 | Printed in U.S.A. References: 1. HUMIRA Injection [package insert]. 2. Data on file. AbbVie Inc.†Based on IMS NPA data: Total HUMIRA prescriptions written by dermatologists from 10/28/11–1/4/13 vs Enbrel®, Stelara®, and Simponi®. All trademarks are properties of their respective owners.

for those with moderate to severe chronic plaque psoriasis

HUMIRA is the #1 prescribed biologic medication by dermatologists. In clinical trials, 7 out of 10 adults with moderate to severe chronic plaque psoriasis saw 75% skin clearance, and the majority of people were clear or almost clear in just 4 months.*

Take a moment to learn more at HUMIRA.com or call 1.800.4HUMIRAAsk a dermatologist if HUMIRA is right for you.

HUMIRA is the #1 Prescribed Biologic Medication by Dermatologists2†

Who is HUMIRA for?HUMIRA is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

Important Safety Information1

What is the most important information I should know about HUMIRA? • Serious infections. HUMIRA can lower

your ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA.

• Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.

Tell your doctor about all of your health conditions, including if you:• Think you have an infection or are being

treated for infection. You should not start HUMIRA if you have any kind of infection unless your doctor says it is okay.

• Have symptoms of an infection, such as: fever, sweats, chills, muscle aches, cough, shortness of breath, blood in phlegm, weight loss, warm, red or painful skin, sores on your body, diarrhea, stomach pain, burning when you urinate, urinating more often than normal, or feeling very tired.

• Get a lot of infections or infections that keep coming back.

• Have diabetes.

• Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB.

• Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis.

• Have or have had hepatitis B.

• Are scheduled for major surgery.

• Have or have had cancer.

• Have numbness or tingling or a nervous system disease, such as multiple sclerosis or Guillain-Barré syndrome.

• Have or had heart failure.

• Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines.

• Are allergic to rubber, latex, or any HUMIRA ingredients.

• Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed.

• Take any other medicines. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).

Call your doctor right away if you have an infection or any symptoms of an infection while on HUMIRA.HUMIRA can cause other serious side effects, including:• Hepatitis B infection in carriers of

the virus. • Allergic reactions.• Nervous system problems. • Blood problems. • Heart failure (new or worsening). • Immune reactions including a

lupus-like syndrome. • Liver problems. • Psoriasis (new or worsening).

Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea.

These are not all of the possible side effects with HUMIRA. For more information, talk to your health care provider.HUMIRA is given by injection under the skin.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1.800.FDA.1088.

If you cannot afford your medication, contact: www.pparx.org or call the toll-free phone number (1.888.4PPA.NOW) for assistance.

With the HUMIRA Protection Plan your co-pay could be as low as $5 a month.*

* Eligibility restrictions apply. See card for details.

Please see additional Patient Information on the following pages.©2013 AbbVie Inc. | North Chicago, IL 60064 | 64Y-1196403 | May 2013 | Printed in U.S.A. References: 1. HUMIRA Injection [package insert]. 2. Data on file. AbbVie Inc.

†Based on IMS NPA data: Total HUMIRA prescriptions written by dermatologists from 10/28/11–1/4/13 vs Enbrel®, Stelara®, and Simponi®. All trademarks are properties of their respective owners.

With HUMIRA, clearer skin is possible. That’s why HUMIRA is the #1 prescribed biologic medication by dermatologists. In clinical trials, 7 out of 10 adults with moderate to severe chronic plaque psoriasis saw 75% skin clearance, and the majority of people were clear or almost clear in just 4 months*.

Prescription assistance for uninsured Americans,

from sea to shining sea.

50 states. 5 years. 50 million prescriptions. In the last 5 years alone, Pfizer Helpful Answers® has helped 5 million uninsured people nationwide get their Pfizer medicines for free or at a savings. We offer more than 90 Pfizer medicines, including those most widely prescribed– the most comprehensive offering of its kind. People with lower incomes are eligible for greater savings.

Let your constituents know that we’re here to help. Call 1-888-304-3762 or visit www.PfizerHelpfulAnswers.com. Filling a need for prescription assistance.

PHA00048 © 2007 Pfizer Inc. All rights reserved.

Bridges connect more than 2 million people

to NYC each day

1 2 3

PHA connects more than 2 million patients

to medicine each year Your connection to helping patients

in need is closer than you think

4 5 6

Connections—Bridges

Pfizer Helpful Answers Broadcast Storyboards

Pfizer Helpful Answer Storyboards

L IV ING ENERGY

magnetic energy

At Ethicon Endo-Surgery, we understand that the right energy in the right hands has the potential to change l ives.

energy conservation

• Maintains tissue temperature at ~100°C with minimal

lateral thermal spread (~1 mm)

• Delivers high, uniform compression with

its patented I-Blade™ design

• Quickly creates vessel seals with minimal smoke,

tissue char, or thermal injury

Where conservation and consistency become living energy

HOPE BRINGS US TOGETHER

Pfizer supports The National Multiple Sclerosis Society’s pioneering work against MS. The foundations’ bright leadership and

human touch brings hope to the table in the fight against MS.

You are not aloneGet together! Get excited! Get healthier!You may feel better about managing your high BP when you learn more about it. Talk to your doctor if you need more information.

You can learn how to:• Get the most out of the BP success

Zone Program • Understand your medicine• Make lifestyle changes to help you get to

BP goal• Stay on track to keep your BP

numbers down

Learn the BP basicsTo get results, you need to learn about BP. High BP is very serious. If left untreated, high BP can lead to heart attack or stroke.* It is important to stay on top of it. You must track your BP numbers over time.

• The BP Success Zone is defined as less than 140/90 to 120/80 mm Hg or below†

• The first number is called systolic. This is the top number. It measures your BP when the heart beats

• The second number is called diastolic. This is the bottom number. It measures your BP between beats

What you need to know about BP:

Know the BP Success Zone

You are not aloneGet together! Get excited! Get healthier!

You may feel better about managing your high BP when you learn more about it. Talk to your doctor if you need more information.

You can learn how to:• Get the most out of the BP Success

Zone Program• Understand your medicine• Make lifestyle changes to help you get to

BP goal • Stay on track to keep your BP

numbers down

6

Your friends, family, and doctor can all work with you to help you lower your BP.

Know the BP Success ZoneLearn the BP basics

To get results, you need to learn about BP. High BP is very serious. If left untreated, it can lead to heart attack or stroke.* It is important to stay on top of it. You must track your BP numbers over time.

What you need to know about BP:• The BP Success Zone is defined as less than 140/90 to

120/80 mm Hg or below†

• The first number is called systolic. This is the top number. It measures your BP when the heart beats

• The second number is called diastolic. This is the bottom number. It measures your BP between beats

Most people can’t feel if they have high BP. they need to visit a doctor and have their BP checked.Be sure to ask your doctor if your BP readings are in the range that is best for you.

120/80

140/90

the BP success Zone Zona Éxito

Most people can’t feel if they have high BP. they need to visit a doctor and have their BP checked.Be sure to ask your doctor if your BP readings are in the range that is best for you.

Family support can help you lower your high BP.

†Individual results may vary. †Los resultados individuales pueden variar.

Your friends, family, and doctor can all work with you to help you lower your BP.

Learn more about BP health.

El Programa y las medicinas en este Programa no son apropriados para personas menores de 18 años.The Program and the drugs in this Program are not intended for anyone under the age of 18.

7

This is the BP Success Zone range

Este es el rango

de la Zona Éxito

* The medicines in this Program are approved to treat high BP, and are not approved to prevent or treat heart attack or stroke resulting from high BP.

* The medicines in this Program are approved to treat high BP, and are not approved to prevent or treat heart attack or stroke resulting from high BP.

2

Learn about high blood pressure (BP) and get help from your family and friends. Stay on track and manage your high BP by eating healthier and taking your medicine.

Being healthy is good not only for you, but also your family. Get them involved. We will show you how.

Your relationship with your doctor is part of staying in the BP Success Zone. You can trust him or her to help. Work with your doctor to set a BP goal in the BP Success Zone. Together you can find a plan that works for you and your family. The first step is to take your BP medicines every day.

Think about what’s most important to you. Is it:• Spending time with your kids or grandkids?• Taking care of parents or other family members?• Helping out your neighbors or your community?• Being able to work?You might think it will be hard to lower your high BP. But with the help of your doctor, family, and friends, you can do it.

BP is a family thingLearn about high blood pressure (BP) and get help from your family and friends. Stay on track and manage your high BP by eating healthier and taking your medicine.

Being healthy is good not only for you, but also your family. Get them involved. We will show you how.

Your relationship with your doctor is part of staying in the BP Success Zone. You can trust him or her to help. Work with your doctor to set a BP goal in the BP Success Zone. Together you can find a plan that works for you and your family. The first step is to take your BP medicines every day.

Think about what’s most important to you. Is it:

• Spending time with your kids or grandkids?

• Taking care of parents or other family members?

• Helping out your neighbors or your community?

• Being able to work?

You might think it will be hard to lower your high BP. But with the help of your doctor, family, and friends, you can do it.

BP is a family thing

The BP Success Zone Program is for adults aged 18 years or older.

3

KEY RESOURCES FOR ADDRESSING CV RISK FACTORS IN AFRICAN AMERICAN PATIENTS

Come together for better control.

BE POWERFUL™ PROGRAMPfizer is committed to improving the health and wellness of patient communities. As part of this commitment, Pfizer launched Be PowerfulTM, a health education program to help improve the health outcomes of African American patients. The Be PowerfulTM program offers health information for patients and their families in the communities where they live.

BE POWERFUL™ BROCHURES:

Take control of your CHOLESTEROL Helps patients understand cholesterol and how to make healthy decisions to positively impact cholesterol rates. Product code number MK271494D

DIABETES information at your fingertips Explains the causes of diabetes and its risk factors and provides suggested questions to ask the doctor. Product code number MK271494B

Managing HIGH BLOOD PRESSUREProvides patients with valuable information about hypertension, its risk factors, and tips on lowering blood pressure. Product code number MK271494C

Get informed about KIDNEY DISEASE Informs patients on testing for kidney disease, the risks factors, and how to keep their bodies healthy. Product code number MK271494E